Cas No.: | 223488-57-1 |
Chemical Name: | Evatanepag |
Synonyms: | 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid;CP-533536;2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid;EVATANEPAG;CP533536 free acid;CP-533536 free acid |
SMILES: | CC(C)(C)C(C=C1)=CC=C1CN(S(C2=CN=CC=C2)(=O)=O)CC3=CC(OCC(O)=O)=CC=C3 |
Formula: | C25H28N2O5S |
M.Wt: | 468.568 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.IC50 value: 0.3 nM (EC50)Target PGE2in vitro: CP-533536 is a potent and selective EP2agonist. CP-533536 demonstrates the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. CP-533536 demonstrates excellent in vitro potency against EP2 and selectivity against a broad panel of other targets. |
References: | [1]. Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. |